Cerebrospinal fluid neuropeptide y levels in major depression and reported childhood trauma

International Journal of Neuropsychopharmacology

Volumn 18, Issue 1, 2015, Pages

  Soleimani, Laili ^a   Oquendo, Maria A ^b,c   Sullivan, Gregory M ^b,c   Mathé, Aleksander A ^d   Mann, J John ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Childhood trauma; CSF; Major depression; Neuropeptide Y

Indexed keywords

NEUROPEPTIDE Y;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHILD ABUSE; CHILD SEXUAL ABUSE; CONTROLLED STUDY; DSM-IV; FAMILY HISTORY; FEMALE; FOOD INTAKE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHYSICAL ABUSE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; STRESS; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; ADOLESCENT; CEREBROSPINAL FLUID; CHILD; LUMBAR PUNCTURE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD ABUSE; DEPRESSIVE DISORDER, MAJOR; HUMANS; MIDDLE AGED; NEUROPEPTIDE Y; SPINAL PUNCTURE; YOUNG ADULT;

EID: 84934970489     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu023     Document Type: Article

References (35)

1. Bach H, Arango V, Huang YY, Leong S, Mann JJ, Underwood MD (2011) Neuronal tryptophan hydroxylase expression in BALB/ cJ and C57Bl/6J mice. J Neurochem 118:1067-1074.
2. Baker DG, et al. (2013) Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology 38:2378-2382.
3. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, Sapareto E, Ruggiero J (1994) Initial reliability and validity of a new retrospective measure of child abuse and neglect. American J Psych 151:1132-1136.
4. Berrettini WH, Doran AR, Kelsoe J, Roy A, Pickar D (1987) Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. Neuropsychopharmacology 1:81-83.
5. Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL (1995) Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol 6:215-222.
6. Caberlotto L, Hurd YL (1999) Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 10:1747-1750.
7. Cervilla JA, Molina E, Rivera M, Torres-Gonzalez F, Bellon JA, Moreno B, Luna JD, Lorente JA, Mayoral F, King M, Nazareth I, Group PSC, Gutierrez B (2007) The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort. Mol Psychiatry 12:748-755.
8. Cohen H, Liu T, Kozlovsky N, Kaplan Z, Zohar J, Mathe AA (2012) The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology 37:350-363.
9. Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HP, Bengel D, Muller CR, Roberts GW, Smeraldi E, Kirov G, Sham P, Lesch KP (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1:453-460.
10. File SE (1980) The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2:219-238.
11. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS (1997) Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, DC: American Psychiatric Press, Inc.
12. First MB, Spitzer RL, Gibbon M, Williams AR (2001) Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version-Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research.
13. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
14. Heilig M (2004) The NPY system in stress, anxiety and depression. Neuropeptides 38:213-224.
15. Heilig M, Wahlestedt C, Ekman R, Widerlov E (1988) Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol 147:465-467.
16. Hou C, Jia F, Liu Y, Li L (2006) CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder. Brain Res 1095:154-158.
17. Husum H, Mathe AA (2002) Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes. Neuropsychopharmacology 27:756-764.
18. Jimenez Vasquez PA, Salmi P, Ahlenius S, Mathe AA (2000) Neuropeptide Y in brains of the Flinders Sensitive Line rat, a model of depression. Effects of electroconvulsive stimuli and d-amphetamine on peptide concentrations and locomotion. Behav Brain Res 111:115-123.
19. Jimenez Vasquez PA, Mathe AA, Thomas JD, Riley EP, Ehlers CL (2001) Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Dev Brain Res 131:149-152.
20. Martinez JM, Garakani A, Yehuda R, Gorman JM (2012) Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety 29:32-38.
21. Morgan CA 3rd, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS (2000) Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry 47:902-909.
22. Nikisch G, Agren H, Eap CB, Czernik A, Baumann P, Mathe AA (2005) Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychop 8:403-410.
23. Nikisch G, Baumann P, Liu T, Mathe AA (2012) Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int J Neuropsychop 15:1051-1061.
24. Nikisch G, Mathe AA (2008) CSF monoamine metabolites and neuropeptides in depressed patients before and after electroconvulsive therapy. Eur Psychiatry 23:356-359.
25. Ordway GA, Stockmeier CA, Meltzer HY, Overholser JC, Jaconetta S, Widdowson PS (1995) Neuropeptide Y in frontal cortex is not altered in major depression. J Neurochem 65: 1646-1650.
26. Pich EM, Agnati LF, Zini I, Marrama P, Carani C (1993) Neuropeptide Y produces anxiolytic effects in spontaneously hypertensive rats. Peptides 14:909-912.
27. Sah R, Ekhator NN, Strawn JR, Sallee FR, Baker DG, Horn PS, Geracioti TD Jr. (2009) Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol Psychiatry 66:705-707.
28. Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF (1986) Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 7:1189-1192.
29. Taniguchi S, Yanase T, Kurimoto F, Takayanagi R, Haji M, Kurose S, Nawata H (1994) Age-related increase in neuropeptide Y-like immunoreactivity in cerebrospinal fluid in women. Fukuoka Igaku Zasshi 85:361-365.
30. Thorsell A, Carlsson K, Ekman R, Heilig M (1999) Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 10:3003-3007.
31. Traskman-Bendz L, Ekman R, Regnell G, Ohman R (1992) HPArelated CSF neuropeptides in suicide attempters. Eur Neuropsychopharmacol 2:99-106.
32. Valdez GR, Koob GF (2004) Allostasis and dysregulation of corticotropin- releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav 79:671-689.
33. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R (1988) Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 22:69-79.
34. Wilkinson PO, Goodyer IM (2011) Childhood adversity and allostatic overload of the hypothalamic-pituitary-adrenal axis: a vulnerability model for depressive disorders. Dev Psychopathol 23:1017-1037.
35. Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D, Mathe AA (2011) Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets 15:1317-1331.